Association Between Somatization and Nonmotor Symptoms Severity in People With Parkinson Disease

Abstract

Objective:

To assess the frequency of somatization and its association with motor, nonmotor symptoms, and quality of life in persons with Parkinson disease (PD).

Methods:

A cross-sectional case–control study was carried out. Assessments included the List of 90 Symptoms somatic factor (SCL-90-R SOM), Movement Disorder Society Unified Parkinson’s Ratings Scale (MDS-UPDRS), Non-Motor Symptom Scale (NMSS), Montreal Cognitive Assessment (MoCA), and Parkinson Questionnaire-8 (PDQ-8).

Results:

A total 93 persons with PD and 93 controls were included. Somatization within the PD group was 2 times more frequent compared to the control group (43% vs 21.5%, P = .003). Persons with PD had higher NMSS total scores (48.6 ± 42.6 vs 28.3 ± 30.4, P = .001). Patients with PD with somatization had worst MDS-UPDRS, NMSS, MoCA, and PDQ-8 (all P < .05).

Conclusion:

Somatization is more frequent in persons with PD compared to healthy controls. Somatization in PD is associated with nonmotor symptoms and worst quality of life.

Keywords

somatization nonmotor symptoms quality of life Parkinson disease

Get full access to this article

View all access options for this article.

References

Mhyre

Boyd

Hamill

Maguire-Zeiss

. Parkinson’s disease. Subcell Biochem. 2012;65:389–455. doi:10.1007/978-94-007-5416-4_16.

Aarsland

Kramberger

. Neuropsychiatric symptoms in Parkinson’s disease. J Parkinsons Dis. 2015;5(3):659–667. doi:10.3233/JPD-150604.

Weintraub

Mamikonyan

. The neuropsychiatry of Parkinson disease: a perfect storm. Am J Geriatr Psychiatry. 2019;27(9):998–1018. doi:10.1016/j.jagp.2019.03.002.

Lipowski

. Somatization: the experience and communication of psychological distress as somatic symptoms. Psychother Psychosom. 1987;47(3-4):160–167. doi:10.1159/000288013.

Carrozzino

Bech

Patierno

, et al. Somatization in Parkinson’s disease: a systematic review. Prog Neuropsychopharmacol Biol Psychiatry. 2017;78:18–26. doi:10.1016/j.pnpbp.2017.05.011.

Postuma

Berg

Stern

, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–1601. doi:10.1002/mds.26424.

Derogatis

Cleary

. Factorial invariance across gender for the primary symptom dimensions of the SCL-90-R. Br J Soc Clin Psychol. 1977;16(4):347–356.

Onofrj

Bonanni

Manzoli

Thomas

. Cohort study on somatoform disorders in Parkinson disease and dementia with Lewy bodies. Neurology. 2010;74(20):1598–1606. doi:10.1212/WNL.0b013e3181df09dd.

Siri

Cilia

De Gaspari

, et al. Psychiatric symptoms in Parkinson’s disease assessed with the SCL-90 R self-reported questionnaire. Neurol Sci. 2010;31(1):35–40. doi:10.1007/s10072-009-0165-0.

10.

Bugalho

Da Silva

Cargaleiro

Serra

Neto

. Psychiatric symptoms screening in the early stages of Parkinson’s disease. J Neurol. 2012;259(1):124–131. doi:10.1007/s00415-011-6140-8.

11.

Carrozzino

Morberg

Siri

Pezzoli

Bech

. Evaluating psychiatric symptoms in Parkinson’s disease by a clinimetric analysis of the Hopkins Symptom Checklist (SCL-90-R). Prog Neuropsychopharmacol Biol Psychiatry. 2018;81:131–137. doi:0.1016/j.pnpbp.2017.10.024.

12.

Carrozzino

Siri

Bech

. The prevalence of psychological distress in Parkinson’s disease patients: the Brief Symptom Inventory (BSI-18) versus the Hopkins symptom checklist (SCL-90-R). Prog Neuropsychopharmacol Biol Psychiatry. 2019;88:96–101. doi:10.1016/j.pnpbp.2018.07.012.

13.

Martinez-Martin

Rodriguez-Blazquez

Alvarez-Sanchez

, et al. Expanded and independent validation of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). J Neurol. 2013;260(1):228–236. doi:10.1007/s00415-012-6624. -1.

14.

Jenkinson

Fitzpatrick

Peto

Greenhall

Hyman

. The PDQ-8: development and validation of a short-form Parkinson’s disease questionnaire. Psychol Health. 2007;12(6):805–814. doi:10.1080/08870449708406741.

15.

Chaudhuri

Martinez-Martin

Brown

, et al. The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord. 2007;22(13):1901–1911. doi:10.1002/mds.21596.

16.

Martinez-Martin

Skorvanek

Rojo-Abuin

, et al. Validation study of the hoehn and yahr scale included in the MDS-UPDRS. Mov Disord. 2018;33(4):651–652. doi:10.1002/mds.27242.

17.

Aguilar-Navarro

Mimenza-Alvarado

Palacios-García

Samudio-Cruz

Gutiérrez-Gutiérrez

Ávila-Funes

. Validity and reliability of the Spanish version of the Montreal cognitive assessment (MoCA) for the detection of cognitive impairment in Mexico. Rev Colomb Psiquiatr. 2018;47(4):237–243. doi:10.1016/j.rcp.2017.05.003.

18.

Guzmán

. Trastorno por somatización: su abordaje en Atención Primaria. Rev Clin Med Fam. 2011;4(3):234–243. doi:10.4321/S1699-695X2011000300009.

19.

Frances

. The new somatic symptom disorder in DSM-5 risks mislabeling many people as mentally ill. BMJ. 2013;346:f1580. doi:10.1136/bmj.f1580.

20.

Cosci

Fava

. The clinical inadequacy of the DSM-5 classification of somatic symptom and related disorders: an alternative trans-diagnostic model. CNS Spectr. 2016;21(4):310–317. doi:10.1017/S1092852915000760.

21.

Kurlansik

Maffei

. Somatic symptom disorder. Am Fam Physician. 2016;93(1):49–54A.

22.

Van Driel

TJW

Hilderink

Hanssen

DJC

De Boer

Rosmalen

JGM

Oude Voshaar

. Assessment of somatization and medically unexplained symptoms in later life. Assessment. 2018;25(3):374–393. doi:10.1177/1073191117721740.

23.

Anderson

Gruber-Baldini

Vaughan

, et al. Impact of psychogenic movement disorders versus Parkinson’s on disability, quality of life, and psychopathology. Mov Disord. 2007;22(15):2204–2209. doi:10.1002/mds.21687.

24.

Tao

Liang

. Effect of subthalamic nuclei electrical stimulation in the treatment of Parkinson’s disease. Cell Biochem Biophys. 2015;71(1):113–117. doi:10.1007/s12013-014-0169-0.

25.

Abraham

Gruber-Baldini

Harrington

Shulman

. The factor structure of the Brief Symptom Inventory-18 (BSI-18) in Parkinson disease patients. J Psychosom Res. 2017;96:21–26. doi:10.1016/j.jpsychores.2017.03.002.

26.

Crimlisk

Bhatia

Cope

David

Marsden

Ron

. Slater revisited: 6 year follow up study of patients with medically unexplained motor symptoms. BMJ. 1998;316(7131):582–586.

27.

Nützel

Dahlhaus

Fuchs

, et al. Self-rated health in multimorbid older general practice patients: a cross-sectional study in Germany. BMC Fam Pract. 2014;15:1. doi:10.1186/1471-2296-15. -1.

28.

Lian

Guo

Zuo

, et al. An investigation on the clinical features and neurochemical changes in Parkinson’s disease with depression. Front Psychiatry. 2019;9:723. doi:10.3389/fpsyt.2018.00723.

29.

Zhu

Pan

, et al. Depression and associated factors in nondemented Chinese patients with Parkinson’s disease. Clin Neurol Neurosurg. 2017;163:142–148. doi:10.1016/j.clineuro.2017.10.031.

30.

Aarsland

Taylor

Weintraub

. Psychiatric issues in cognitive impairment. Mov Disord. 2014;29(5):651–662. doi:10.1002/mds25873.

31.

Valkovic

Harsany

Hanakova

Martinkova

Benetin

. Nonmotor symptoms in early- and advanced-stage Parkinson’s disease patients on dopaminergic therapy: how do they correlate with quality of life? ISRN Neurol. 2014;2014:587302. doi:10.1155/2014/587302.

32.

Robottom

Gruber-Baldini

Anderson

, et al.

What determines resilience in patients with Parkinson’s disease?

Parkinsonism Relat Disord. 2012;18(2):174–177. doi:10.1016/j.parkreldis.2011.09.021.

33.

Carrozzino

. Clinimetric approach to rating scales for the assessment of apathy in Parkinson’s disease: a systematic review. Prog Neuropsychopharmacol Biol Psychiatry. 2019;94:109641. doi:10.1016/j.pnpbp.2019.109641.